NHS-IL12 for Solid Tumors

Clinical Trial ID NCT01417546

PubWeight™ 9.86^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01417546

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	The development of immunoconjugates for targeted cancer therapy.	Nat Rev Clin Oncol	2014	1.49
2	Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.	Clin Cancer Res	2000	1.38
3	Trial Watch: Immunostimulatory cytokines.	Oncoimmunology	2012	1.19
4	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.	Cancer Immunol Res	2015	1.18
5	Interleukin 12: still a promising candidate for tumor immunotherapy?	Cancer Immunol Immunother	2014	1.17
6	New insights into IL-12-mediated tumor suppression.	Cell Death Differ	2014	1.09
7	Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.	Cancer Res	2000	1.03
8	Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.	Clin Cancer Res	1999	0.91
9	The tumor microenvironment in esophageal cancer.	Oncogene	2016	0.83
10	The immunocytokine NHS-IL12 as a potential cancer therapeutic.	Oncotarget	2014	0.83
11	Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma.	PLoS One	2015	0.77
12	Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.	Semin Oncol	2014	0.77
13	Defining the Value of a Comparative Approach to Cancer Drug Development.	Clin Cancer Res	2015	0.77